Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

The newest precision medicine tool: Prostate cancer organoids

  • - Urology / Nephrology News
  • Sep 05, 2014
  • Comments
  • Viewed: 2743
Tags: | cancer treatment | metastatic prostate cancer | prostate cancer | prostate cancer cell |

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory, giving researchers an exciting new tool to test cancer drugs and personalize cancer treatment.

The researchers, whose results were published today in Cell, successfully grew six prostate cancer organoids from biopsies of patients with metastatic prostate cancer and a seventh organoid from a patient’s circulating tumor cells. Organoids are three-dimensional structures composed of cells that are grouped together and spatially organized like an organ. The histology, or tissue structure, of the prostate cancer organoids is highly similar to the metastasis sample from which they came. Sequencing of the metastasis samples and the matched organoids showed that each organoid is genetically identical to the patient’s cancer from which it originated.

“Identifying the molecular biomarkers that indicate whether a drug will work or why a drug stops working is paramount for the precision treatment of cancer,” said Yu Chen, MD, PhD, Assistant Attending Physician in the Genitourinary Oncology Service and Human Oncology and Pathogenesis Program at MSK. “But we are limited in our capacity to test drugs - especially in the prostate cancer setting, where only a handful of prostate cancer cell lines are available to researchers.”

With the addition of the seven prostate cancer organoids described in the Cell paper, Dr. Chen’s team has effectively doubled the number of existing prostate cancer cell lines.

“We now have a new resource at our disposal that captures the molecular diversity of prostate cancer. This will be an invaluable tool we can use to test drug sensitivity,” he added.

The use of organoids in studying cancer is relatively new, but the field is exploding quickly according to Dr. Chen. In 2009, Hans Clevers, MD, PhD, of the Hubrecht Institute in the Netherlands demonstrated that intestinal stem cells could form organoids. Dr. Clevers is the lead author on a companion piece also published in Cell today that describes how to create healthy prostate organoids. Dr. Chen’s paper is the first to demonstrate that organoids can be grown from prostate cancer samples.

The prostate cancer organoids can be used to test multiple drugs simultaneously, and Dr. Chen’s team is already retrospectively comparing the drugs given to each patient against the organoids for clues about why the patient did or didn’t respond to therapy. In the future, it’s possible that drugs could be tested on a patient’s organoid before being given to the patient to truly personalize treatment.

After skin cancer, prostate cancer is the most common cancer in American men - about 233,000 new cases will be diagnosed in 2014. It is also the second leading cause of cancer death in men; 1 in 36 men will die of the disease.

Despite its prevalence, prostate cancer has been difficult to replicate in the lab. Many mutations that play a role in its growth are not represented in the cell lines currently available. Cell lines can also differ from their original source, and because they are composed of single cells, they do not offer the robust information that an organoid - which more closely resembles a living organ - can provide.


Researchers from Weill Cornell Medical College and the Hubrecht Institute of the Royal Netherlands Academy of Arts and Sciences contributed to the research.

The research was funded by the National Institutes of Health under grants CA140946, CA092629, CA155169, and CA116337, the US Department of Defense, the Movember Foundation, the Geoffrey Beene Cancer Research Center at MSK, and the STARR Cancer Consortium. In addition, a large portion of funding was provided by a Stand Up To Cancer (SU2C)-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant. SU2C is a program of the Entertainment Industry Foundation whose scientific partner is the American Association for Cancer Research.

About Memorial Sloan Kettering

We are the world’s oldest and largest private cancer center, home to more than 13,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world.


Andrea Baird
.(JavaScript must be enabled to view this email address)
Memorial Sloan-Kettering Cancer Center

Bookmark and Share

Post a comment [ + Comment here + ]

There are no comments for this entry yet. [ + Comment here + ]

Your details

* Required field

Please enter the word you see in the image below:

Comments are moderated by our editors, so there may be a delay between submission and publication of your comment. Offensive or abusive comments will not be published.

three-agent chemotherapy1 - ontario health insurance plan1 - neuroendocrine prostate cancer1 - glomerulonephritis3 - specialized high-fat1 - autosomal-dominant polycystic kidney disease2 - noncalcium calculi1 - nephrology9 - mesonephric duct1 - tgen1 - slow prostate growth1 - sex cords1 - neurological disorder1 - coffee4 - crescenteric glomerulonephritis1 - prostate inflammation1 - lower kidney function2 - pyelocaliceal diverticula1 - androgen-independent prostate cancer1 - nephron-sparing surgery1 - urinary ions2 - rare kidney disease1 - polycyctic kidneys1 - vagina4 - cyclophosphamide1 - possible treatments1 - cancerous tumor1 - high blood sugar1 - pancreatic cancer2 - stone disease4 -